Novartis Aktie
103,34
EUR
+3,82
EUR
+3,84
%
97,56
CHF
+3,76
CHF
+4,01
%
Kursziele der Novartis-Aktie in CHF
Das durchschnittliche Kursziel beinhaltet alle Analysen eines Analysten und nicht nur die jeweils aktuellste Analyse, die im Chart dargestellt wird.
Diese Analysten bewerten die Novartis-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| UBS AG | 111,00 CHF | +13,78% | 27.01.2025 | |
| Jefferies & Company Inc. | 100,00 CHF | +2,50% | 20.01.2025 | |
| Goldman Sachs Group Inc. | 100,00 CHF | +2,50% | 09.01.2025 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 86,00 CHF | -11,85% | 07.01.2025 | |
| Bernstein Research | 115,00 CHF | +17,88% | 07.01.2025 | |
| Deutsche Bank AG | 100,00 CHF | +2,50% | 17.12.2024 | |
| JP Morgan Chase & Co. | 95,00 CHF | -2,62% | 03.12.2024 | |
| Barclays Capital | 85,00 CHF | -12,87% | 21.11.2024 | |
| DZ BANK | - | - | 19.07.2024 |
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 5 | 4 | 0 | 134,70 GBP | +18,87% |
| Bayer | 1 | 8 | 0 | 24,12 EUR | +10,29% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 2 | 2 | 1 | 9,68 EUR | +13,15% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 2 | 6 | 1 | 16,49 GBP | +17,58% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 7 | 1 | 0 | 184,00 EUR | +21,25% |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 3 | 5 | 1 | 99,00 CHF | +1,48% |
| Pfizer Inc. | 3 | 3 | 0 | 31,20 USD | +15,94% |
| Roche AG (Genussschein) | 2 | 4 | 3 | 275,67 CHF | -3,88% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 5 | 2 | 1 | 110,57 EUR | +6,95% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |